A5009757221- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Metabolism and Genetic Disorders
- Neuroendocrine Tumor Research Advances
- Diet and metabolism studies
- Renal cell carcinoma treatment
- Colorectal Cancer Screening and Detection
- Mitochondrial Function and Pathology
- Peroxisome Proliferator-Activated Receptors
- Amino Acid Enzymes and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Pancreatitis Pathology and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Cardiac, Anesthesia and Surgical Outcomes
- Gastric Cancer Management and Outcomes
- Hip and Femur Fractures
- Ocular Oncology and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Anorectal Disease Treatments and Outcomes
- Neonatal Health and Biochemistry
- Hernia repair and management
- Hepatitis B Virus Studies
University of Liverpool
2013-2024
Manchester Royal Infirmary
2022
Manchester University NHS Foundation Trust
2022
McGill University
2021
Royal Manchester Children's Hospital
2021
Imperial College London
2021
MRC Lifecourse Epidemiology Unit
2021
University of Southampton
2021
Cancer Research UK
2015-2020
Faculdade de Agudos
2017
BackgroundThe ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better tumour response capecitabine alone advanced or metastatic We aimed determine efficacy safety compared monotherapy for cancer.MethodsWe did a phase 3, two-group, open-label, multicentre, randomised at 92 hospitals England, Scotland, Wales,...
4505 Background: Patients with borderline resectable pancreatic cancer have poor survival and low resection rates. Neoadjuvant therapy may improve the outcome for these patients. The aim of this trial was to determine feasibility efficacy a comparison immediate surgery versus neoadjuvant GEMCAP or FOLFIRINOX CRT. Methods: Eligible patients NCCN defined (following central review baseline CT scan) biopsy proven were randomised (stratified by centre) receive surgery, either 2 cycles GEMCAP, 4...
Alkaptonuria (AKU) is a serious genetic disease characterised by premature spondyloarthropathy. Homogentisate-lowering therapy being investigated for AKU. Nitisinone decreases homogentisic acid (HGA) in AKU but the dose-response relationship has not been previously studied.Suitability Of In 1 (SONIA 1) was an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, study. The primary objective to investigate effect of different doses nitisinone once daily...
In single-centre studies, postoperative complications are associated with reduced fitness. This study explored the relationship between cardiorespiratory fitness variables derived by cardiopulmonary exercise testing (CPET) and in-hospital morbidity after major elective colorectal surgery.Patients underwent preoperative CPET recording of morbidity. Receiver operating characteristic (ROC) curves logistic regression were used to assess morbidity.Seven hundred three patients from six centres in...
Aims The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy metastatic UM. Pre-clinical studies support synergistic cytotoxic for inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib paclitaxel. Patients Methods Seventy-seven patients UM who had not received prior chemotherapy were randomised alone, or paclitaxel without...
4516 Background: The ESPAC-4 trial demonstrated that adjuvant GEM/CAP for pancreatic cancer significantly improved survival compared to GEM monotherapy. aim of this study is evaluate the long-term outcomes in trial. Methods: Patients with ductal adenocarcinoma were randomized within 12 weeks surgery (stratified R0/R1 resection margin status and country) have either six 4-week cycles IV alone or oral CAP. primary endpoint was five-year survival; secondary endpoints toxicity relapse free...
BackgroundScreening for pancreatic ductal adenocarcinoma (PDAC) in populations at high risk is recommended. Individuals with new-onset type 2 diabetes mellitus (NOD) are the largest high-risk group PDAC. To facilitate screening, we sought biomarkers capable of stratifying NOD subjects into those (T2DM) and less prevalent PDAC-related (PDAC-DM), a form 3c DM commonly misdiagnosed as T2DM.MethodsUsing mass spectrometry- immunoassay-based methodologies multi-stage analysis independent sample...
Perianal abscess is common. Traditionally, postoperative perianal cavities are managed with internal wound packing, a practice not supported by evidence. The aim of this randomized clinical trial (RCT) was to assess if non-packing less painful and it associated adverse outcomes.The Postoperative Packing Abscess Cavities (PPAC2) multicentre, RCT (two-group parallel design) adult participants admitted an NHS hospital for incision drainage primary abscess. Participants were 1:1 (via online...
Alkaptonuria (AKU) is an ultrarare autosomal recessive disorder resulting from a deficiency of homogentisate 1,2 dioxygenase (HGD), enzyme involved in the catabolism phenylalanine and tyrosine. Loss HGD function prevents metabolism homogentisic acid (HGA), leading to increased levels plasma HGA urinary excretion. Excess becomes deposited collagenous tissues subsequently undergoes polymerisation, principally cartilages loaded joints, process known as ochronosis. This results early-onset,...
Background There is limited evidence for the use of enhanced recovery after surgery (ERAS) in patients undergoing hepatectomy, and impact evolution ERAS over time has not been examined. This study sought to evaluate effect an evolving program hepatectomy colorectal liver metastases (CRLM). Methods A multimodal was introduced 2/2008. Consecutive CRLM between 2/2008 9/2012 were included study. Data collected prospectively. Retrospective analysis compared early cohort (2/2008–4/2010) with a...
Alkaptonuria (AKU) is a serious genetic disease due to defect in tyrosine metabolism, leading increased serum levels of homogentisic acid (HGA). Nitisinone decreases HGA AKU, but the concentration-response relationship has not been previously reported.To determine between concentrations nitisinone and effect on both tyrosine; secondly steady-state pharmacokinetics AKU patients.Thirty-two patients with received either 1, 2, 4, or 8 mg daily. Urine were measured during 24 h at baseline (before...
LBA4006 Background: The ESPAC-3 trial compared adjuvant GEM with 5-fluorouracil/folinic acid for resected pancreatic cancer. is the standard of care based on similar survival and less toxicity. ESPAC-4 aimed to determine whether combination chemotherapy GEM/CAP improved monotherapy. Methods: Patients ductal adenocarcinoma were randomized within 12 weeks surgery (stratified R0/R1 resection margin status country) have either six 4 week cycles IV alone or oral CAP. primary endpoint was overall...
Alkaptonuria (AKU) is a disorder of tyrosine/protein metabolism leading to accumulation homogentisic acid. Clinical management historically recommended reducing dietary protein intake, especially in childhood, which has since been discredited the literature. For first time, analysis baseline cross-sectional nutritional surveillance data from large cohort AKU patients presented, clinical implications all aspects treatment planning.Seventy-four (mean 55 years) admitted National Centre (NAC),...
Background Alkaptonuria (AKU) is present from birth, yet clinical effects are considered to appear later in life. Morbidity of AKU, irreversible, secondary ochronosis. Age ochronosis onset not clearly known. Nitisinone profoundly lowers homogentisic acid (HGA), the metabolic defect AKU. also arrests and slows progression However, tyrosinaemia post-nitisinone has been associated with corneal keratopathy, rash cognitive impairment HT 1. The optimal time start nitisinone AKU unknown. Methods In...
<b>Background:</b> Three-session days were introduced in our endoscopy unit to accommodate the increased demand resulting from introduction of National Health Service Bowel Cancer Screening Programme (BCSP). Cecal intubation rate (CIR) and adenoma detection (ADR) may decline with time during a standard working day, but data are lacking for an extended three-session day. We assessed colonoscopy performance <b>Methods:</b> Colonoscopies performed year 2011 retrospectively analyzed. The CIR ADR...
Incomplete colonoscopy indicated for the detection of neoplasia occurs in 2-23% patients, but there is little information on long-term outcome such patients.All patients who underwent over 5 years at Royal Liverpool University Hospital with a follow-up up to were identified.The risk colorectal cancer (CRC) was 2.9% (312/10 580) all undergoing colonoscopy. For failed colonoscopy, five-fold higher [14.3% (99/693)]. The mean age 61 and 58% female. Following incomplete finding additional CRC,...
LBA4006 The full, final text of this abstract will be available at abstracts.asco.org 2:00 PM (EDT) on Friday, June 3, 2016, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.